Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer

BackgroundSerplulimab has shown promising results in the treatment of extensive-stage small cell lung cancer (ES-SCLC). This study aimed to evaluate the cost-effectiveness of serplulimab combination therapy compared to chemotherapy alone in patients with ES-SCLC from the Chinese healthcare system pe...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Zhiwei Zheng, Hongcai Chen, Hongfu Cai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Subjects:	serplulimab cost-effectiveness extensive-stage small cell lung cancer chemotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1259574/full